New Indicator For Liver Cancer Screening PIVKA-II IVD Products Tumor Maker Assay For Clinical In Vitro Diagnostic
Brand Name:Zecen
Certification:CE, ISO13485
Model Number:PIVKA-II
Minimum Order Quantity:10 boxes
Delivery Time:15 working days
Payment Terms:L/C, D/A, D/P, T/T, Western Union, MoneyGram
Contact Now
Add to Cart
Active Member
Location:
Taizhou Jiangsu
Address:
Building G62, Phase 4 Plant, China Medical City, Taizhou City, Jiangsu Province
Supplier`s last login times:
within 1 hours
Product Details
Company Profile
Product Details
New indicator for liver cancer screening(PIVKA-II) test kit Tumor Maker Assay for Clinical In Vitro Diagnostic
Clinical Significance
In recent years, a large number of clinical studies have shown that PIVKA-II has good sensitivity and specificity, so PIVKA-IIP is gradually used as an indicator for liver cancer screening and diagnosis in clinical diagnosis.
Abnormal prothrombin increased, seen in more than 90% of
hepatocellular carcinoma, the average can be as high as 900μg/L.
APT elevation was also seen in 40% to 50% of metastatic liver
cancers, but the mean value was lower.
In hepatocellular carcinoma with low alpha-fetoprotein (AFP)
levels, APT tends to be elevated. It has been reported that for
liver cancer with AFP lower than 400 μg/L, APT was higher than 300
μg/L in 57% of cases. Therefore, simultaneous detection of AFP and
APT can improve the diagnosis rate of low-AFP HCC from 48% to 68%.
In addition, mildly elevated APT is also seen in chronic hepatitis
and vitamin K deficiency, which can be corrected with vitamin K
supplementation at this time.
Prothrombin is the precursor of thrombin, and abnormal prothrombin refers to prothrombin synthesized by liver cells in the absence of vitamin K. The normal value of abnormal prothrombin should be less than 20μg/L. Abnormal prothrombin can be used as an indicator for judging hepatocellular carcinoma. When suffering from hepatocellular carcinoma, it will affect the generation of prothrombin precursor, resulting in a large amount of abnormal thrombin. Abnormal prothrombin, alpha-fetoprotein and other tests are commonly used in clinical practice, as well as pathological examinations to clarify the nature of the lesions.
CLIA Reagents of Tumor Maker(PIVKA-II)
| Test Item | PIVKA-II |
| Luminescent Principle | Enzymatic chemiluminescence |
| Luminescent Markers | AP(alkaline phosphatase) |
| Specification | 100 Test/Kit for CIA series |
| Principle | Sandwich method |
| Component | Magnetic Beads |
| Calibrator Low | |
| Calibrator High | |
| Anti-A/Anti-B | |
| Control 1 | |
| Control 2 | |
| Accessories Required But Not Provided | Substrate |
| Washing solution | |
| Sample material | Serum/Plasma/Whole Blood |
| Storage | 2-8℃ |
New Indicator For Liver Cancer Screening PIVKA-II IVD Products Tumor Maker Assay For Clinical In Vitro Diagnostic
Inquiry Cart
0